Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines

Joseph Yeboah, Tamar S. Polonsky, Rebekah Young, Robyn L. McClelland, Joseph C. Delaney, Farah Dawood, Michael J. Blaha, Michael D. Miedema, Christopher Sibley, J. Jeffrey Carr, Gregory L. Burke, David C. Goff, Bruce M. Psaty, Philip Greenland, David M. Herrington

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background-In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. Methods and Results-Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE 7.5% who may warrant statin therapy considerations.

Original languageEnglish (US)
Pages (from-to)916-922
Number of pages7
JournalCirculation
Volume132
Issue number10
DOIs
StatePublished - Sep 8 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
Guidelines
Cardiovascular Diseases
Population
Coronary Disease
Atherosclerosis
Therapeutics
Stroke
Myocardial Infarction
Demography

Keywords

  • cholesterol
  • coronary artery calcium
  • epidemiology
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • primary prevention

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. / Yeboah, Joseph; Polonsky, Tamar S.; Young, Rebekah; McClelland, Robyn L.; Delaney, Joseph C.; Dawood, Farah; Blaha, Michael J.; Miedema, Michael D.; Sibley, Christopher; Carr, J. Jeffrey; Burke, Gregory L.; Goff, David C.; Psaty, Bruce M.; Greenland, Philip; Herrington, David M.

In: Circulation, Vol. 132, No. 10, 08.09.2015, p. 916-922.

Research output: Contribution to journalArticle

Yeboah, J, Polonsky, TS, Young, R, McClelland, RL, Delaney, JC, Dawood, F, Blaha, MJ, Miedema, MD, Sibley, C, Carr, JJ, Burke, GL, Goff, DC, Psaty, BM, Greenland, P & Herrington, DM 2015, 'Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines', Circulation, vol. 132, no. 10, pp. 916-922. https://doi.org/10.1161/CIRCULATIONAHA.115.016846
Yeboah, Joseph ; Polonsky, Tamar S. ; Young, Rebekah ; McClelland, Robyn L. ; Delaney, Joseph C. ; Dawood, Farah ; Blaha, Michael J. ; Miedema, Michael D. ; Sibley, Christopher ; Carr, J. Jeffrey ; Burke, Gregory L. ; Goff, David C. ; Psaty, Bruce M. ; Greenland, Philip ; Herrington, David M. / Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. In: Circulation. 2015 ; Vol. 132, No. 10. pp. 916-922.
@article{c697f8b6516844e2a2b74418e07a70f7,
title = "Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines",
abstract = "Background-In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5{\%} based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. Methods and Results-Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE 7.5{\%} who may warrant statin therapy considerations.",
keywords = "cholesterol, coronary artery calcium, epidemiology, hydroxymethylglutaryl-CoA reductase inhibitors, primary prevention",
author = "Joseph Yeboah and Polonsky, {Tamar S.} and Rebekah Young and McClelland, {Robyn L.} and Delaney, {Joseph C.} and Farah Dawood and Blaha, {Michael J.} and Miedema, {Michael D.} and Christopher Sibley and Carr, {J. Jeffrey} and Burke, {Gregory L.} and Goff, {David C.} and Psaty, {Bruce M.} and Philip Greenland and Herrington, {David M.}",
year = "2015",
month = "9",
day = "8",
doi = "10.1161/CIRCULATIONAHA.115.016846",
language = "English (US)",
volume = "132",
pages = "916--922",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines

AU - Yeboah, Joseph

AU - Polonsky, Tamar S.

AU - Young, Rebekah

AU - McClelland, Robyn L.

AU - Delaney, Joseph C.

AU - Dawood, Farah

AU - Blaha, Michael J.

AU - Miedema, Michael D.

AU - Sibley, Christopher

AU - Carr, J. Jeffrey

AU - Burke, Gregory L.

AU - Goff, David C.

AU - Psaty, Bruce M.

AU - Greenland, Philip

AU - Herrington, David M.

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Background-In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. Methods and Results-Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE 7.5% who may warrant statin therapy considerations.

AB - Background-In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. Methods and Results-Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE 7.5% who may warrant statin therapy considerations.

KW - cholesterol

KW - coronary artery calcium

KW - epidemiology

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84941362173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941362173&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.016846

DO - 10.1161/CIRCULATIONAHA.115.016846

M3 - Article

VL - 132

SP - 916

EP - 922

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 10

ER -